Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

EBS $31.53 3.7700 +13.58%
DRNA $5.88 0.6800 +13.08%
IDRA $2.56 0.2500 +10.82%
PGNX $6.33 0.6100 +10.66%
CCXI $6.04 0.5000 +9.03%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TKMR $3.44 -0.4500 -11.57%
NWBO $0.54 -0.0123 -2.22%
RDUS $54.09 -1.1100 -2.01%
CTIX $1.29 -0.0200 -1.53%
RDHL $13.89 -0.2100 -1.49%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

KU Submits Application for Next-Level NCI Cancer Designation

(Kansas City Business Journal) Sept 27, 2016 - After years of planning, The University of Kansas Cancer Center took a crucial step toward joining the highest echelons of cancer research.
read article 

ASCO Calls on Congress to Fund Cancer Moonshot Initiative

(ASCO in Action) Sept 27, 2016 - ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, moderated a panel discussion today on Capitol Hill that focused on the National Cancer Moonshot Blue Ribbon Panel Report.
read article 

Ask Legislators to Join Congressional Sign-on Letter Opposing Part B Demo

(ASCO in Action) Sept 27, 2016 - ASCO and other stakeholder groups have raised significant concerns regarding the Medicare Part B Drug Demo, citing the proposal's flawed premise, experimental nature, and lack of important patient protections. The society has repeatedly called on the Centers for Medicare & Medicaid Services (CMS) to withdraw the demo and focus on physician reimbursement reform efforts currently underway.
read article 

ARIAD Announces Regulatory Approval for Iclusig® (ponatinib) in Japan

(ARIAD) Sept 28, 2016 - ARIAD Pharmaceuticals, Inc. today announced that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for Iclusig® (ponatinib) for the treatment of chronic myeloid leukemia (CML) resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
read corporate press release 

Separating Hope from Hype in the Latest Cancer Treatment 'Revolution'

(STAT) Sept 27, 2016 - There's new hope that a much-hyped class of immunotherapies could revolutionize cancer treatment: Data released this week from an early test on patients stirred hope that the first such therapy could hit the market soon.
read article 

Pfizer Completes Acquisition of Medivation

(StreetInsider) Sept 28, 2016 - Pfizer Inc. today announced the successful completion of its acquisition of Medivation, Inc. As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for $81.50 per share in cash, without interest, subject to any required withholding of taxes.
read article 

Cancer Immunotherapy Is Moving Fast. Here's What You Need to Know

(Washington Post/To Your Health) Sept 28, 2016 - The idea of using the body's immune system to fight cancer has been around for a century, but only in the past half a dozen years have dramatic breakthroughs begun rocking the medical world.
read article (free registration required) 

Furor Over Drug Prices Puts Patient Advocacy Groups in Bind

(New York Times) Sept 27, 2016 - Public anger over the cost of drugs has burned hot for a year, coursing through social media, popping up on the presidential campaign, and erupting in a series of congressional hearings, including one last week over the rising price of the allergy treatment EpiPen.
read article 

Cyberattacks On Personal Health Records Growing 'Exponentially'

(Washington Post/Power Post blog) Sept 28, 2016 - This year marks the 20th anniversary of the Health Insurance Portability and Accountability Act, better known as HIPAA.
read article (free registration required) 

Need a Ride to a Doctor's Appointment? Uber Partner Tests Service In Phila. Area

(Philadelphia Business Journal) Sept 27, 2016 - Circulation, a Boston-based provider of non-emergency medical transportation services and new Uber partner, has selected two health-care providers in the Philadelphia region to test what it is describing as its "customizable, patient-centric digital transportation platform."
read article 

Controversy Erupts Around Baby With Three Biological Parents

(Forbes) Sept 28, 2016 - A U.S. fertility specialist, foiled by U.S. regulations, took his tools to Mexico to tweak human cells into developing into the world's first three-parent baby, an infant born in April 2016 who carries DNA from two mothers and one father.
read article 

Is the FDA Too Cozy With Drug Companies?

(TIME) Sept 28, 2016 - People who work at the U.S. Food and Drug Administration (FDA) as medical reviewers are responsible for parsing the risks and benefits of a particular drug before it gets the agency's approval.
read article 

Sanofi Gets $43 Mln U.S. Funding To Spur Zika Vaccine Development

(Business Insider/Reuters) Sept 26, 2016 - Sanofi SA said on Monday the U.S. Department of Health and Human Services approved $43.18 million in funding to accelerate the development of a Zika vaccine, as part of efforts to prevent the infection.
read article 

GW Pharma's Epidiolex Hits Mark For Rare Type Of Epilepsy

(BioPharma Dive) Sept 27, 2016 - GW Pharmaceuticals saw its stock soar on Monday after announcing its cannabidiol drug Epidiolex helped reduce the frequency of seizures among patients with a rare form of childhood-onset epilepsy, hitting its primary endpoint in the third successful Phase 3 study of the drug.
read article 

Expert Panel Recommends Expansion Of Services With No Cost Sharing For Women

(Kaiser Health News) Sept 27, 2016 - The list of preventive services that women can receive without paying anything out of pocket under the health law could grow if proposed recommendations by a group of mostly medical providers are adopted by federal officials later this year.
read article 

Hypofractionated RT Halves Tx Time for Infirm NSCLC Patients

(Medscape Medical News) Sept 27, 2016 - In patients with stage II/III non–small cell lung cancer (NSCLC) who are unable to receive surgery or chemoradiation, accelerated hypofractionated radiation can achieve outcomes similar to those achieved using conventional radiotherapy, with reduced toxicities, according to an interim analysis of a phase 3 trial.
read article (free registration required) 

Hypofractionated RT Can Reduce Treatment Time By One-Third With Comparable QOL For Prostate Cancer Patients

(ASTRO Annual Meeting) Sept 26, 2016 - For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy (RT) offers comparable health-related quality of life outcomes in one-third less treatment time than conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
read article 

Intermediate Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone

(ASTRO Annual Meeting) Sept 26, 2016 - For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology (ASTRO).
read press release 

Cervical and Endometrial Cancer Patients Report Fewer Side Effects And Better Quality Of Life With IMRT

(ASTRO Annual Meeting) Sept 26, 2016 - Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
read press release 

Review & Outlook: A Drug Cartel at the FDA

(Wall Street Journal) Sept 26, 2016 - A new rule will produce a lawsuit rush and raise prices for generics.
read article (paid subscription required) 

From CARTs To Checkpoints, Here's What's Coming In Immuno-Oncology

(Forbes) Sept 27, 2016 - Shares of Kite Pharma were up more than 12% to $61.80 in pre-market trading this morning, on news that the company’s engineered immune cells, called chimeric antigen receptor T-cells (CARTs), are performing well in a clinical trial in lymphoma patients.
read article 

Stock of Vienna-Based Cel-Sci Tumbles On FDA Notice

(WTOP-Radio [Washington, DC]) Sept 27, 2016 - Vienna, Virginia-based biotechnology company Cel-Sci, currently running late-stage clinical trials with patients for its head and neck cancer treatment, watched its stock fall more than 30 percent in early Tuesday trading after a notice from the Food and Drug Administration.
read article 

MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers

(NASDAQ) Sept 26, 2016 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.
read article 

Biomarkers Used as Outcomes: FDA Wants to Hear More on Examples

(Regulatory Focus) Sept 26, 2016 - The US Food and Drug Administration (FDA) is seeking comment from interested stakeholders to determine the utility of a list of examples of biomarkers used as outcomes in development of FDA-approved new molecular entities and new biological therapeutics.
read article 

Color Genomics Raises $45 Million to Expand Genetic Testing

(Bloomberg) Sept 27, 2016 - Color Genomics Inc., the three-year-old startup aiming to democratize genetic testing, sealed $45 million in funding as it seeks to make its tests for cancer more affordable and accessible, the company announced Tuesday.
read article